Focus on the New Menopause Management Horizon: Improving Outcomes Through Managed Care

Focus on the New Menopause Management Horizon: Improving Outcomes Through Managed Care

Focus on the New Menopause Management Horizon: Improving Outcomes Through Managed Care

Will new data and treatments revolutionize menopause and vasomotor symptom management? Nonhormonal treatments may shift clinical and payer paradigms.

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Are you ready to see what is on the horizon to more effectively navigate vasomotor symptoms (VMS)? Join Drs. Dunn, Owens, and Nelson as they discuss highlights from a symposium held at AMCP 2022 featuring the latest data on the impact of menopause and evolving treatments options. They provide guidance, context, and recommendations for the medical management of VMS beyond estrogen. The nonhormonal treatment options that are currently being studied represent a new horizon for both patients and payers.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Jeffrey D. Dunn, PharmD, MBA
    Chief Clinical Officer, Cooperative Benefits Group
    Salt Lake City, UT

    No relevant relationships reported.

    Gary M. Owens, MD
    President, Gary Owens Associates, Inc.
    Ocean View, DE

    Consulting Fees: Icon, Magnolia Innovation, Octave Biosciences, Payer Sciences

    Anita L. Nelson, MD
    Professor and Chair, Obstetrics and Gynecology
    College of Osteopathic Medicine of the Pacific
    Western University of Health Science
    Pomona, CA

    Grants/ Research: Agile Therapeutics, Mylan Phharmaceuticals/ Viatris Pharmaceuticals, Organon/ Merck, Sagami Rubber Industries, Sebela Pharmaceuticals
    Honoraria/ Speakers Bureau: Bayer HealthCare, Mayne Pharma, Organon/ Merck, Myovant/ Pfizer, TherapeuticsMD
    Consulting Fees/ Advisory Board: Agile Therapeutics, Bayer HealthCare, Mayne Pharma, Organon/ Merck, Myovant/Pfizer, TherapeuticsMD

    Reviewers/Content Planners/Authors:

    • Stephen Chavez has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Estelle Perera has nothing to disclose.
    • Anna Trentini has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Discuss data on the individual and public health burden associated with vasomotor symptoms (VMS)
    • Describe endocrinologic changes during menopause that lead to the root cause of VMS
    • Compare and contrast the risks and benefits of current treatments for VMS to address barriers to optimal medical management
    • Evaluate the latest clinical trial data on investigational agents for VMS that are nearing approval
  • Target Audience

    This activity is designed to meet the educational needs of managed care professionals as well as healthcare providers who manage female patients.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

     Global Learning Collaborative (GLC) designates this live symposium activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 15 minutes of nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .25 AAPA Category 1 CME credits. PAs should claim only the credit commensurate with the extent of their participation in the activity.

    This curriculum has been approved for .25 contact hours .025 CEUs by Global Learning Collaborative (GLC).  GLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The Universal Activity Number for this program is JA0006235-0000-22-018-H01-P.  This learning activity is enduring based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (

  • Provider(s)/Educational Partner(s)

    Omnia Education is the leading provider of education for women’s health professionals. Our activities are recognized nationwide for providing credible, relevant, and practical information on issues impacting the female patient. Additionally, our unique focus has transformed the CME learning environment, and our ability to help learners recognize and overcome barriers to optimal performance and optimal patient outcomes has positioned us as a leader in women’s health education.

  • Commercial Support

    This activity is supported by an independent educational grant from Astellas.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Omnia Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Omnia Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments


We’re glad to see you’re enjoying Omnia Education…
but how about a more personalized experience?

Register for free